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ABSTRACT 
Lithium is the treatment for acute mania and bipolar disorders. Ever since its introduction in the 
psychiatric arsenal, case reports of toxicity have been appearing in the literature at regular intervals. 
This study was thus carried out to study the presentation and associated features of lithium toxicity. In 
this retrospective study, case record files of all patients suspected to have developed lithium toxicity 
during a five year period were retrieved. It was found that toxicity presented most commonly with 
cerebellar symptoms and appeared at lower serum levels. Lithium could be restarted albeit at a lower 
dose and with a gradual titration in a number of cases. 
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Lithium remains the paradigmatic 
treatment for acute mania and prophylaxis of 
bipolar disorders (Post, 1995). Lithium has a low 
therapeutic index and case reports abound in 
published literature about its toxic effects (e.g. 
Andrade et al .1987, 1988; Kumar et al ,1999; 
Sampath et al.1980, Cohen and Cohen, 1974; 
Thomas,1979, Rifkin et al.,1973, Thornton and 
Pray,1975; Shopsin and Gershon,1973; 
Gangadharetal.,1993). In a number of them (e.g. 
Andrade et al.,1987, 1988; Kumar et al 1999; 
Sampath et al., 1980; Gangadhar et al., 1993) the 
toxicity was evidenced in the therapeutic range. 
Various precipitating factors like concomitant 
antipsychotic administration (e.g. Cohen and 
Cohen,1974; Thomas,1979; Rifkin et al.,1973; 
Shopsin and Gershon,1973; Thornton and Pray, 
1975), organicity (Shopsin and Gershon.1973; 
Thornton and Pray,1975; Stayhorn and Nash, 
1977) and a diagnosis of schizophrenia (Shopsin 
and Gershon,1973) were put forward to account 
for the toxicity Though there have been a number 
of reviews (eg Stayhorn and Nash. 1977; Schou, 
1984, Roy et al ,1999) attempting to synthesize 
the findings of the case reports there have been 
few studies on assessing the toxicity (Baastrup 
et al.,1976; Goldney and Spence,1986). Both 
these studies were retrospective in nature and 
attempted to find out whether lithium toxicity 
occurred more frequently when combined with 
antipsychotic drugs. This study was thus carried 
out to study the presentation and associated 
features of Lithium toxicity. 
MATERIAL AND METHOD 
This was a retrospective study conducted 
in Central Institute of Psychiatry, Ranchi. This is 
a tertiary referral centre for psychiatric problems 
catering to the entire Eastern Indian population. 
Patients are admitted in different wards 
according to the admitting unit and gender of 
the patient A twenty four hour report is prepared 
daily in each ward in the night and contains the 
details of all patients who are a management 
problem or have physical problems. 
The daily reports of all wards were 
screened by the members of the research team 
for the period between 1st August 1993 to 31st 
July 1998. The date and the name of those 
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patients were noted who were mentioned as 
having either probable lithium toxicity or had 
descriptions suggestive of toxicity such as 
nausea, vomiting, diarrhea, tremors, unsteady 
gait, unclear speech or confusion. The cases in 
which the reports suggested a clear cut 
extrapyramidal syndrome were excluded from 
the study. 
The case record files of the noted patients 
were removed from the record section of the 
institute by the registration number obtained by 
tallying the patients name and date from the 
admission register. Members of the research 
team reviewed the case record files and a 
diagnosis was ascribed to the physical problem. 
In case of any doubt, the case was discussed 
amongst members of the research team and a 
consensus diagnosis was reached at. 
A diagnosis of Lithium toxicity was made 
if the patient was receiving Lithium and had signs 
and symptoms suggestive of lithium toxicity 
(Jefferson and Greist,1995) which could not be 
explained otherwise. 
RESULTS 
A total of 38 patients were identified as 
having probable lithium toxicity Out of these, 
files could be traced for 36 patients. On reviewing 
the files, a diagnosis of lithium toxicity was 
ascribed to 18 cases. 3 cases were excluded , 
as serum lithium levels were not recorded in the 
files leaving a final sample size of 15. The details 
of the sample are given in table 1. 
This consisted of 10 males and 5 females. 
The diagnosis was first episode mania in 2 cases, 
bipolar mania in 12 cases and bipolar depression 
in 1 case. The mean daily lithium dosage was 
1000±209.6 with a median and mode of 900 mg 
and a range of 900-1650 mg daily. The mean 
age of the sample was 33.4±10.93 with a range 
of 19 to 55 years. 
The concomitant treatment at the time of 
toxicity was antipsychotics in 11 cases 
(Haloperidoi in 9 and Chlorpromazine in 2), 
antidepressants and haloperidoi in 1 case, ECT 
and haloperidoi in 1 case and a combination of 
lithium, carbamazepine and chlorpromazine in 
one case. The average daily dose of 
antipsychotics was 10 2±6.12 mg in haloperidoi 
equivalents (range 0-20 mg). 
The interval between initiation or hiking of 
lithium dose and the appearance of features of 
toxicity was 11.47 days with a median of 10 and 
a mode of 7 days. The range was 5-45 days. On 
removing the outlier of 45 days, the median was 
7 days and the mean was 9 days. 
The mean lithium level recorded in the 
file immediately after toxicity was suspected was 
1.44±0.66 (range 0.3-2.5) m mol/L. This serum 
lithium level was obtained using flame 
photometry method The drugs were stopped and 
serum lithium was obtained the next day. 
Patients with serum lithium levels less 
than 1.5 m mol/L were significantly younger than 
those with serum lithium level more than 1.5 m 
mol/L (mean age was 26.13±5.25 years in 
patients with serum lithium level less than 1.5 
compared to 41 72±9.76 in those with serum 
lithium level more than 1.5, T test, p=0.002). 
There was no significant difference in sex, 
haloperidoi dose, lithium dose, precipitating factor 
and rechallenge of lithium between patients with 
serum level more than 1.5 m mol/L and less than 
1.5 m mol/L. 
Possible precipitating factors were 
identified in 3 patients. This consisted of NSAID 
administration for two days prior to symptoms in 
1 patient and low grade fever for 2-3 days prior 
to symptoms in 2 patients. 
The toxicity features were divided into two 
groups - neurotoxicity and others The 
neurotoxicity group had cerebellar and/or corticai 
manifestations. Cerebellar signs consisted of a 
mixture of ataxia, impaired tandem walk and 
finger nose test, slurred speech, hypotonia, 
pendular jerks and coarse tremors. The cortical 
signs consisted of a mixture of confusion, 
exaggerated jerks, seizures and hypertonia. All 
other presentations such as nausea, vomiting, 
loose motions, loss of appetite were grouped 
together in the second group. 
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TABLE 
SHOWING THE DEMOGRAPHIC, TREATMENT AND TOXICITY FEATURES OF THE SAMPLE 
Age 
20 
30 
26 
32 
32 
19 
28 
22 
37 
45 
42 
50 
25 
38 
55 
Sex 
Male 
Male 
Male 
Female 
Male 
Male 
Male 
Female 
Male 
Female 
Female 
Male 
Male 
Female 
Male 
Halo-
peridol 
dose 
15 
10 
5 
15 
15 
15 
20 
5 
6.5 
10 
20 
0 
6.5 
5 
5 
Lithium 
dose 
(mg) 
900 
900 
900 
900 
1200 
1650 
1050 
1200 
900 
900 
900 
900 
900 
900 
900 
Lithium 
level 
mmol/L 
0.3 
0.5 
0.7 
0.9 
0.9 
1.3 
1.5 
1.5 
1.6 
1.8 
1.9 
2.0 
2.0 
2.2 
2.5 
Ppt 
Factor 
Fever 
Fever 
NSAID 
Rechall 
Yes 
No 
Yes 
Yes 
No 
Yes 
No f/up 
No 
Yes 
No f/up 
Yes 
No 
Yes 
No 
No 
Rechall 
dose 
(mg) 
900 
X 
900 
600 
X 
900 
X 
X 
600 
X 
750 
X 
1050 
X 
X 
Rechall 
outcome 
No S/E 
X 
No S/E 
S/E 
X 
No S/E 
X 
X 
S/E 
X 
No S/E 
X 
No S/E 
X 
X 
Final 
Out 
come 
F.R. 
F.R. 
F.R 
F.R. 
F.R. 
F.R 
F.R 
F.R. 
FR. 
Sym 
FR. 
F.R 
F.R. 
F.R. 
F.R. 
Symptoms of toxicity 
Tremor, nystag 
Seizure, Confusion, ataxia, 
dysarthria, imp.tan., nystag. 
Dysarthria, ataxia, tremor, 
imp. tan., dys. 
Confusion, drowsy, dys. ataxia 
Vomiting, confusion, ataxia, 
nystag. 
Confusionjoose motion .tremor: 
Hypotonia, nystag., ataxia, 
pen. tremors 
Tremors, ataxia, confusion, 
sedation 
Dysarthia, ataxia, nystagmus 
Ataxia, dysarthria, confusion, 
hypertonia, nystag., pen. 
Confusion, tremors, dysarthria 
ataxia 
Nausea, decreased appetite 
and loose motion 
Dys., tremor, nystag 
Nausea, loose motion 
Decreased appetite, loose 
motions 
F/up • Follow up; S/E - Side effects, FR - Full recovery; 
NSAID - Diclofenac tablets. Nystag - nystagmus, pen. 
dys - dysdiadokinesis; tremors - Coarse tremor 
A total of 12 patients presented with 
neurological symptoms for toxicity out of which 
7 displayed cortical symptoms and all 12 
displayed cerebellar symptoms. The mean 
serum lithium level was significantly less in 
patients with cerebellar symptoms than those 
without (mean serum lithium level was 1 24+0.57 
in patients with cerebellar symptoms and 
2 23±0 25 in those without cerebellar symptoms, 
't' test. p=0.012). There was no significant 
difference in the mean serum lithium levels in 
patients with or without cortical or other 
symptoms (f test, p=ns) 
Out of the 15 patients, 2 were lost on follow 
up, 6 were not rechallenged with lithium and 7 
were readministered lithium. Out of these 7, 2 
patients were those who had a precipitating 
factor For rechallenge. the lithium was started 
at 600 mg and hiked at 150 mg intervals every 
Sym-Symptomatic at discharge; Rechall- Rechallenge; 
pendular jerks; imp. tan. - impaired tandem walk; 
week. Out of the 7, three patients were 
established on the same dose prior to toxicity 
without a recurrence. All three had only 
cerebellar manifestation and one of them had 
an antecedent in terms of fever. Out of the 
remaining four patients, 2 redeveloped similar 
toxicity on a lesser dose Both of them had 
neurological manifestations and none had 
antecedents The remaining two patients were 
maintained at 150 mg less than the dose at which 
toxicity was experienced. One of them had an 
antecedent and both had neurological 
symptoms. 
The three patients excluded due to lack 
of serum lithium levels consisted of 2 males and 
1 female They were receving lithium in the range 
of 900 - 1350 mg daily along with haloperidol. 
All three had both cortical and cerebellar 
symptoms. One patient was reexposed to lithium 
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and did not develop any toxicity. 
DISCUSSION 
Most of our patients were on combination 
with antipsychotics which has been postulated 
to be a risk factor for neurotoxicity (Cohen and 
Cohen,1974; Thomas,1979; Rifkin et al.,1973, 
Thornton and Pray, 1975). All of these were case 
reports with haloperidol used in doses upto 100 
mg and lithium upto 2400 mg. Furthermore, the 
case of Cohen and Cohen (1974) had fever also. 
This issue was addressed in retrospective studies 
by Baastrup et al. (1976) and Goldney and Spence 
(1986) who found no evidence of lithium toxicity 
in patients with concurrent neuroleptic 
administration. All our cases had daily haloperidol 
equivalent doses of less than 20 mg per day and 
the modal lithium dose of 900 mg. Thus it is quite 
unlikely that the toxicity in our patients was due 
to a combination of neuroleptics and lithium. 
Except for one case, the modal duration of 
interval between toxicity and hiking the dose was 
7 days which agrees with the pharmacokinetic 
five half lives of lithium to attain the new serum 
level. Thus it could be that there exists 
individualized threshold levels for the occurrence 
of toxicity. This is borne by the finding that two 
patients could be maintained without toxicity at a 
lesser dose. Of interest is the finding that three 
patients could be maintained on the same dose 
when the dosage was built gradually. Thus it is 
not only the threshold which is important but also 
the rate at which it is attained. Schou (1984) reports 
restarting of lithium in three patients without any 
signs of lowered tolerance or aggravation of 
neurological disturbances. Thus an attempt of 
lithium rechallenge may be attempted on patients 
experiencing toxicity. 
Another finding of interest is that 
cerebellar symptoms were the most common 
presentation and occurred at a significantly 
lesser serum level. Cerebeller symptoms at 
therapeutic serum levels have been reported as 
features of toxicity (Andrade et al.,1987, 1988; 
Kumar et al.,1999; Sampath et al.,1980) and a 
recent review (Roy et al.,1999) concluded that 
lithium had a tropism specific to the cerebellum. 
Thus it seems that toxicity developing at lower 
serum levels predisposes a person to develop 
the cerebellar form 
Fourteen of the fifteen patients improved. 
This suggests that if prompt action is undertaken, 
the signs of lithium toxicity are reversible. In 
accordance with the finding of Schou (1984) and 
Andrade et al. (1987, 1988) the remnant deficit 
in the lone case was cerebellar in nature. This 
good prognosis could also be due to tne fact that 
in most of the cases the toxicity occured at 
therapeutic serum levels and in only four cases 
was the level more than 2 m mol/L. 
In the majority of the cases (80%) no 
precipitating factor could be identified. 
Furthermore, the lithium level was mostly in the 
therapeutic range. One must keep in mind that 
the serum was drawn immediately after suspicion 
of toxicity and thus this estimation was done less 
than twelve hours after the last dose. In most of 
the cases it was done approximately six hours 
after the last dose and thus the twelve hour 
serum lithium values might have been lower. This 
suggests that the toxicity in these patients might 
be idiosyncratic in nature. In the case reported 
by Gangadhar et al. (1993), even though the 
serum lithium level was at the lower end of 
therapeutic range, RBC lithium levels revealed high 
intracellular concentrations. It has been discussed 
by Bell et al. (1993) that intraerythrocyte lithium 
levels correlate better with cerebral levels and blood 
cell: plasma ratio vary from individual to individual 
with some individuals genetically predisposed to 
take up more lithium intracellular^ from a given 
dose than others (Dorus etal 1975) This might 
be the explanation for the development of 
neurotoxicity at the therapeutic serum levels. 
Lithium level monitoring as well as the RBC : 
Plasma lithium ratio may thus be a better indicator 
of neurotoxicity. 
In conclusion, our study reports that the 
occurence of toxicity after lithium administration 
at therapeutic levels might be idiosyncratic. 
There are individual variations in the threshold for 
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the appearance of toxicity and that gradual titration 
may be required to achieve that threshold. In 
younger patients, toxicity appears at lower serum 
lithium levels If toxicity occurs at a therapeutic 
level, lithium may be attempted to be reintroduced 
gradually. Cerebellar symptoms as manifestation 
of toxicity are the most common manifestation 
and appear at lower serum lithium levels. Lithium 
toxicity may be reversible if tackled early. 
One must keep in mind that the study was 
retrospective in design and some cases might 
have been missed during the review of the daily 
reports. The sample size was also too small to 
arrive at a definitive conclusion. However, as 
the drugs were used in the dosage and 
combination commonly used in clinical settings, 
this low sample size might reflect the 
idiosyncratic nature of the toxicity. 
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NOTES AND NEWS 
DR. L.P. SHAH ORATION AWARD 
This Award has been instituted out of an endowment received from Dr. LP Shah, a past President of 
the IPS. 
RULES 
1. Dr. LP. Shah Oration Award will be declared one year in advance at every Annual Conference of the 
Society. 
2. Any Psychiatrist/Mental Health Professional working in the field of Psychiatry in India or abroad is 
eligible for this award. 
3. Any member of the IPS West Zone can propose the name of the individual to receive the Dr. L.P. 
Shah Oration Award. The proposal with six copies of the nominee must be submitted to the 
Chairperson, Award Sub-Committee, Before 31st August each year together with a written consent 
of the nominee. 
4. The nomination will be assessed by a panel of 3 judges independently and the individual who 
scores the highest pooled marks shall be selected to receive the Award and deliver the Oration. In 
case of a tie. the nominations shall be rated again by a panel of judges The decision of the panel 
of judges as ratified by the Executive Committee of IPS West Zone shall be final. 
5. The speaker can choose any topic for Oration. He shall intimate the title of the Oration to the 
Chairperson, Award Sub-Committee and to Chairperson, Scientific Sub-Committee well in advance 
prior to the conference. 
6. The Oration paper may be published in the Zonal journal, with editorial corrections, if necessary. 
7. The speaker shall be given a CERTIFICATE/SCROLL AND A LUMP SUM for the Oration. 
8. No person shall win the Award more than once. 
9 The Executive Committee of the IPS West Zone and the Chairperson, Awards Sub-Committee 
shall have the authority to nominate the individual to receive the 'Dr. L.P. Shah Oration Award'. 
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